Patents Assigned to Scinopharm Taiwan, Ltd.
  • Patent number: 10919905
    Abstract: Crystalline form S1 of irinotecan free base characterized by a powder X-ray diffraction pattern with peaks at about 8.7±0.2, 13.1±0.2, 14.5±0.2, 17.4±0.2, 18.4±0.2, 20.9±0.2, 24.0±0.2 and 27.5±0.2 degrees two-theta degrees two-theta, and crystalline form S2 of irinotecan free base characterized by a powder X-ray diffraction pattern with peaks at about 7.1±0.2, 10.6±0.2, 12.4±0.2, 20.6±0.2, 21.6±0.2 and 24.2±0.2 degrees two-theta.
    Type: Grant
    Filed: March 26, 2020
    Date of Patent: February 16, 2021
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Yuan-Xiu Liao, Yuan-Chang Huang
  • Patent number: 10703728
    Abstract: In certain aspects, the invention provides a novel crystalline form of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides a processe for preparing the novel crystalline form of olaparib. The process includes forming a solution comprising crude olaparib and an organic solvent; adding the solution to an anti-solvent to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form III of olaparib.
    Type: Grant
    Filed: June 18, 2019
    Date of Patent: July 7, 2020
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Wen-Wei Lin, Tsung-Cheng Hu, Yuan-Chang Huang, Yung-Hung Chang, Kuan-Hsun Wang
  • Patent number: 10435395
    Abstract: Crystalline form S1 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 10.7±0.2, 16.2±0.2, 19.9±0.2, 22.1±0.2, 24.7±0.2, and 25.9±0.2 degrees two-theta, crystalline form S2 of lifitegrast characterized by a powder X-ray diffraction pattern with peaks at about 16.4±0.2, 24.9±0.2, and 26.2±0.2 degrees two-theta, and processes of making thereof are provided.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: October 8, 2019
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Wen-Wei Lin, Tsung-Cheng Hu, YuanChang Huang, Ming-Chih Wu
  • Patent number: 10428052
    Abstract: The present disclosure provides efficient, economical, and improved processes for synthesizing lifitegrast and intermediates thereof. The currently discloses processes provide a direct synthetic route, avoiding protection or deprotection steps. The currently disclosed process also provides processes for synthesizing lifitegrast using a reduced number of synthetic steps.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: October 1, 2019
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Ming-Chih Wu, Tsung-Yu Hsiao
  • Patent number: 10385142
    Abstract: A process for preparing sugammadex sodium comprising: reacting a ?-cyclodextrin of formula I with a halogenating agent in the presence of N-methyl-2-pyrrolidone to provide a compound of formula II; and reacting the compound of formula II with 3-mercapto propionic acid in the presence of a sodium base and an organic solvent to provide sugammadex sodium formula III: wherein X in formula II is halo.
    Type: Grant
    Filed: January 17, 2018
    Date of Patent: August 20, 2019
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: ChiaYing Lee, ShangHong Chen
  • Patent number: 10138215
    Abstract: The present invention provides processes for the preparation of ataluren. Intermediates for preparing ataluren are also provided.
    Type: Grant
    Filed: June 19, 2017
    Date of Patent: November 27, 2018
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Tsung-Yu Hsiao, Yu-Hui Huang, Wei-Yu Chen
  • Patent number: 10138211
    Abstract: In certain aspects, the invention provides crystalline forms of olaparib (4-[(3-[(4-cyclopropylcarbonyl)piperazin-4-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one). In related aspects, the invention provides processes for preparing the crystalline forms of olaparib. The processes include: forming a solution comprising crude olaparib and an organic solvent; adding an anti-solvent to the solution to form a slurry comprising a precipitate; isolating the precipitate; and drying the precipitate to obtain a crystalline form I of olaparib or a crystalline form II of olaparib.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: November 27, 2018
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Wen-Wei Lin, Tsung-Cheng Hu, Yuan-Chang Huang
  • Patent number: 10118937
    Abstract: A process for making ixazomib citrate of formula VI comprising reacting a compound of formula V with citric acid to form ixazomib citrate of formula VI: wherein R is hydrogen or an amide protecting group.
    Type: Grant
    Filed: January 3, 2018
    Date of Patent: November 6, 2018
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Tsung-Yu Hsiao, Jyh-Hsiung Liao
  • Patent number: 10100017
    Abstract: Provided herein are novel processes and methods for making 4-[(3-[(4-cyclopropylcarbonyl)piperazin-1-yl]carbonyl)-4-fluorophenyl]methyl(2H)phthalazin-1-one (Olaparib) and intermediates thereof. Olaparib is a poly ADP ribose polymerase (PARP) inhibitor useful in the treatment of cancers. Benefits of the present disclosure include the use of less toxic compounds and improved yields.
    Type: Grant
    Filed: August 23, 2017
    Date of Patent: October 16, 2018
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Tsung-Yu Hsiao, Yung-Hung Chang
  • Patent number: 10072039
    Abstract: The present invention provides improved processes of preparing Fondaparinux sodium comprising converting a compound of formula ABCDE4 to Fondaparinux sodium at a reaction pH of no more than about 9.0. In some embodiments, the intermediates for the synthesis of Fondaparinux sodium, are also provided.
    Type: Grant
    Filed: July 25, 2013
    Date of Patent: September 11, 2018
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Lung-Huang Kuo, Shang-Hong Chen, Li-Ting Wang, Wen-Li Shih, Yuan-Xiu Liao
  • Patent number: 9834561
    Abstract: The present invention provides efficient, economical, and improved methods for synthesizing ibrutinib and intermediates thereof. The invention involves a unique biphasic acylation reaction system which advantageously allows for easy separation of ibrutinib from the reaction mixture without additional extraction and wash steps. The isolated ibrutinib formed using the methods described herein can be useful in the preparation of an amorphous form of ibrutinib. In some embodiments, the isolated ibrutinib produced by the processes described herein is a homogenous solution of ibrutinib and DMSO which may be directly used in the formation of the amorphous polymorph. In some embodiments, the isolated ibrutinib is solid ibrutinib. The solid ibrutinib may also be used in the formation of amorphous ibrutinib.
    Type: Grant
    Filed: October 27, 2016
    Date of Patent: December 5, 2017
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Tsung-Yu Hsiao, MengFen Ho, HsinChang Tseng, WenShing Tsao, YuanChang Huang, Wei-Shuo Lo
  • Patent number: 9834533
    Abstract: The present invention provides processes for preparing SGLT2 inhibitors, such as dapagliflozin and empagliflozin.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: December 5, 2017
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Tsung-Yu Hsiao, Jyh-Hsiung Liao
  • Patent number: 9771390
    Abstract: The present invention provides novel processes for the preparation of regadenoson having the formula (I). In some embodiments, the intermediates for the synthesis of regadenoson are also provided.
    Type: Grant
    Filed: December 10, 2013
    Date of Patent: September 26, 2017
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Xiaoheng Zhang, Lijun Mei
  • Patent number: 9765026
    Abstract: The present invention provides novel crystalline forms of apremilast hemitoluene solvate, apremilast hydrate, and apremilast anhydrate and an amorphous form of apremilast, and processes for the preparation of these forms.
    Type: Grant
    Filed: August 24, 2016
    Date of Patent: September 19, 2017
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Hsiao-ping Fang, Wei-Shuo Lo, Kuan Hsun Wang, Yu-Sheng Lin, Tsung-Cheng Hu, YuanChang Huang
  • Publication number: 20170240520
    Abstract: The present invention provides processes for preparing SGLT2 inhibitors, such as dapagliflozin and empagliflozin.
    Type: Application
    Filed: February 10, 2017
    Publication date: August 24, 2017
    Applicant: ScinoPharm Taiwan, Ltd.
    Inventors: Tsung-Yu Hsiao, Jyh-Hsiung Liao
  • Patent number: 9670234
    Abstract: This invention provides a novel method for the preparation of 2,3-disubstituted -4-oxy-cyclopentan1-one compounds that are useful for the synthesis of prostaglandins and prostaglandin analogs of industrial relevance. The method comprises the metal-catalyzed asymmetric 1,4-conjugate addition of vinylboron compounds to 2-substituted -4-oxy-cyclopent-2-en-1-ones. This method relies on the use of less toxic, easily-handled reagents, and can be performed under milder conditions than offered by some conventional methods, affording 2,3-disubstituted-4-oxy-cyclopentan-1-one compounds enantio- and diastereoselectively, which are precursors to the said prostaglandin and prostaglandin analogs, in high yield.
    Type: Grant
    Filed: July 9, 2015
    Date of Patent: June 6, 2017
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Julian Paul Henschke, Ping-Yu Wu, Hsyueh-Liang Wu, Wen-Hsien Wen
  • Patent number: 9643931
    Abstract: The present invention provides a process for the efficient preparation of enzalutamide.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: May 9, 2017
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Yuan-Xiu Liao, Jiunn-Cheh Guo, Wen-Li Shih, Shang-Hong Chen
  • Patent number: 9604990
    Abstract: Crystalline forms of pemetrexed diacid are provided (Forms 1 and 2) which are readily produced for either laboratory-scale or industrial scale. Processes for the preparation of Forms 1 and 2 are also provided.
    Type: Grant
    Filed: October 28, 2015
    Date of Patent: March 28, 2017
    Assignee: SCINOPHARM TAIWAN, LTD.
    Inventors: Ying-Tzu Lin, Kuan-Hsun Wang, Wei-Shuo Lo, Wen-Wei Lin, Wan-Yin Cheng
  • Patent number: 9556218
    Abstract: The present invention provides intermediates for preparing abiraterone, and processes for preparing abiraterone and intermediates thereof. The intermediates include a compound of formula (IV): wherein R represents a hydroxy-protecting group.
    Type: Grant
    Filed: June 26, 2014
    Date of Patent: January 31, 2017
    Assignee: ScinoPharm Taiwan, Ltd.
    Inventors: Lung-Huang Kuo, Hsiao-Ping Fang, Ming-Feng Wu, Yu-Sheng Chang
  • Patent number: 9465032
    Abstract: The present disclosure relates to a method for selecting a pool of molecules comprising detecting if the pool of molecules has binding specificity to an agent. A method for selecting a pool of biological markers in or on a cell, a composition comprising a pool of molecules, a method for delivering a therapeutic agent, and a method for diagnosing a condition in a subject are also provided.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: October 11, 2016
    Assignees: SCINOPHARM TAIWAN LTD., NATIONAL YANG-MING UNIVERSITY
    Inventors: Hardy W. Chan, Chi-Ying Huang